MoonLake Immunotherapeutics (MLTX)
Largest Insider Buys in Sector
MLTX Stock Price History Chart
MLTX Stock Performance
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Activity of MoonLake Immunotherapeutics
Over the last 12 months, insiders at MoonLake Immunotherapeutics have bought $0 and sold $131.01M worth of MoonLake Immunotherapeutics stock.
On average, over the past 5 years, insiders at MoonLake Immunotherapeutics have bought $39.32M and sold $68.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 58,839 shares for transaction amount of $3.52M was made by Chen Bihua (10 percent owner) on 2023‑10‑05.
List of Insider Buy and Sell Transactions, MoonLake Immunotherapeutics
| 2024-10-04 | Sale | 2M 2.9134% | $50.00 | $100M | -7.99% | |||
| 2024-10-04 | Sale | director | 171,000 0.2676% | $53.72 | $9.19M | -7.99% | ||
| 2024-02-29 | Sale | Chief Executive Officer | 4,740 0.0077% | $55.89 | $264,919 | -3.40% | ||
| 2024-02-28 | Sale | Chief Executive Officer | 56,065 0.0898% | $55.00 | $3.08M | -17.93% | ||
| 2024-02-28 | Sale | Chief Scientific Officer | 60,000 0.0961% | $55.00 | $3.3M | -17.93% | ||
| 2024-02-27 | Sale | Chief Executive Officer | 62,810 0.1006% | $55.00 | $3.45M | -14.81% | ||
| 2024-02-27 | Sale | Chief Scientific Officer | 58,922 0.0944% | $55.00 | $3.24M | -14.81% | ||
| 2024-02-21 | Sale | Chief Executive Officer | 1,125 0.0018% | $55.27 | $62,179 | -12.70% | ||
| 2024-02-21 | Sale | Chief Scientific Officer | 1,078 0.0017% | $55.30 | $59,618 | -12.70% | ||
| 2024-02-20 | Sale | Chief Executive Officer | 20,000 0.0335% | $57.44 | $1.15M | -15.30% | ||
| 2024-02-20 | Sale | Chief Scientific Officer | 20,000 0.0335% | $57.44 | $1.15M | -15.30% | ||
| 2024-02-16 | Sale | Chief Executive Officer | 20,000 0.035% | $60.15 | $1.2M | -21.96% | ||
| 2024-02-16 | Sale | Chief Scientific Officer | 20,000 0.035% | $60.15 | $1.2M | -21.96% | ||
| 2024-02-15 | Sale | Chief Executive Officer | 20,000 0.0351% | $60.18 | $1.2M | -22.11% | ||
| 2024-02-15 | Sale | Chief Scientific Officer | 20,000 0.0351% | $60.16 | $1.2M | -22.11% | ||
| 2024-02-14 | Sale | Chief Scientific Officer | 20,000 0.0364% | $62.42 | $1.25M | -25.18% | ||
| 2023-12-20 | Sale | Chief Financial Officer | 5,264 0.0089% | $58.34 | $307,102 | -16.45% | ||
| 2023-12-19 | Sale | Chief Financial Officer | 94,736 0.1634% | $59.22 | $5.61M | -19.52% | ||
| 2023-10-05 | 10 percent owner | 58,839 0.1027% | $59.90 | $3.52M | -24.48% | |||
| 2023-10-04 | 10 percent owner | 67,814 0.1132% | $57.32 | $3.89M | -18.08% |
Insider Historical Profitability
| Chen Bihua | 10 percent owner | 8494151 13.4691% | $52.17 | 8 | 0 | <0.0001% |
| Helix Holdings LLC | 430000 0.6818% | $52.17 | 1 | 0 | <0.0001% |